Publications by authors named "Brian J Long"

Claim this Profile
D
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
Wonsuk Chang, Michael D Altman, Charles A Lesburg, Samanthi A Perera, Jennifer A Piesvaux, Brian J Long

J Med Chem· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models.
Peter Georgiev, Eric S Muise, Douglas E Linn, Marlene C Hinton, Yun Wang, Brian J Long

Mol Cancer Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
Samanthi A Perera, Johnny E Kopinja, Yanhong Ma, Eric S Muise, Jason Laskey, Long Cui, Brian J Long

Mol Cancer Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An orally available non-nucleotide STING agonist with antitumor activity.
Bo-Sheng Pan, Samanthi A Perera, Jennifer A Piesvaux, Jeremy P Presland, Gottfried K Schroeder, Brian J Long

Science· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Stergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, Ramesh K Ramanathan, Alex A Adjei, Brian J Long

JCI Insight· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
Robert N Booher, Harold Hatch, Brian M Dolinski, Thi Nguyen, Lauren Harmonay, Brian J Long

PLoS One· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
Gongjie Liu, Stacey A Taylor, Cindy H Marrinan, Yunsheng Hsieh, W Robert Bishop, Brian J Long

Int J Cancer· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultra-performance hydrophilic interaction liquid chromatography/tandem mass spectrometry for the determination of everolimus in mouse plasma.
Yunsheng Hsieh, Gerica Galviz, Brian J Long

Rapid Commun Mass Spectrom· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Stacey A Taylor, Cindy H Marrinan, Gongjie Liu, Lissette Nale, W Robert Bishop, Brian J Long

Gynecol Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Gonjgie Liu, Cindy H Marrinan, Stacey A Taylor, Stuart Black, Andrea D Basso, Brian J Long

Anticancer Drugs· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Andrea D Basso, Asra Mirza, Gongjie Liu, Brian J Long, W Robert Bishop

J Biol Chem· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Danijela Jelovac, Gauri Sabnis, Brian J Long, Luciana Macedo, Olga G Goloubeva

Cancer Res· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Danijela Jelovac, Luciana Macedo, Venkatesh Handratta, Brian J Long, Olga G Goloubeva

Clin Cancer Res· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.
Venkatesh D Handratta, Danijela Jelovac, Brian J Long, Ritesh Kataria, Ivo P Nnane

J Steroid Biochem Mol Biol· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
Brian J Long, Danijela Jelovac, Venkatesh Handratta, Apinya Thiantanawat, Nicol MacPherson

J Natl Cancer Inst· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens.
Apinya Thiantanawat, Brian J Long, Angela M Brodie

Cancer Res· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens.
Angela Brodie, Danijela Jelovac, Brian J Long

Clin Cancer Res· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Brian J Long, Danijela Jelovac, Apinya Thiantanawat, Angela M Brodie

Clin Cancer Res· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis